Dynavax Technologies Share Holder Equity 2010-2022 | DVAX
Dynavax Technologies share holder equity from 2010 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
Dynavax Technologies Annual Share Holder Equity
(Millions of US $) |
| 2021 |
$222 |
| 2020 |
$59 |
| 2019 |
$8 |
| 2018 |
$63 |
| 2017 |
$200 |
| 2016 |
$89 |
| 2015 |
$187 |
| 2014 |
$100 |
| 2013 |
$186 |
| 2012 |
$115 |
| 2011 |
$100 |
| 2010 |
$52 |
| 2009 |
$6 |
Dynavax Technologies Quarterly Share Holder Equity
(Millions of US $) |
| 2022-03-31 |
$287 |
| 2021-12-31 |
$222 |
| 2021-09-30 |
$68 |
| 2021-06-30 |
$83 |
| 2021-03-31 |
$100 |
| 2020-12-31 |
$59 |
| 2020-09-30 |
$69 |
| 2020-06-30 |
$58 |
| 2020-03-31 |
$12 |
| 2019-12-31 |
$8 |
| 2019-09-30 |
$39 |
| 2019-06-30 |
$11 |
| 2019-03-31 |
$43 |
| 2018-12-31 |
$63 |
| 2018-09-30 |
$97 |
| 2018-06-30 |
$131 |
| 2018-03-31 |
$166 |
| 2017-12-31 |
$200 |
| 2017-09-30 |
$204 |
| 2017-06-30 |
$141 |
| 2017-03-31 |
$97 |
| 2016-12-31 |
$89 |
| 2016-09-30 |
$108 |
| 2016-06-30 |
$139 |
| 2016-03-31 |
$164 |
| 2015-12-31 |
$187 |
| 2015-09-30 |
$211 |
| 2015-06-30 |
$75 |
| 2015-03-31 |
$75 |
| 2014-12-31 |
$100 |
| 2014-09-30 |
$122 |
| 2014-06-30 |
$151 |
| 2014-03-31 |
$174 |
| 2013-12-31 |
$186 |
| 2013-09-30 |
$72 |
| 2013-06-30 |
$85 |
| 2013-03-31 |
$98 |
| 2012-12-31 |
$115 |
| 2012-09-30 |
$130 |
| 2012-06-30 |
$145 |
| 2012-03-31 |
$88 |
| 2011-12-31 |
$100 |
| 2011-09-30 |
$36 |
| 2011-06-30 |
$46 |
| 2011-03-31 |
$36 |
| 2010-12-31 |
$52 |
| 2010-09-30 |
$23 |
| 2010-06-30 |
$13 |
| 2010-03-31 |
$-2 |
| 2009-12-31 |
$6 |
| 2009-09-30 |
$18 |
| 2009-06-30 |
$25 |
| 2009-03-31 |
$20 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.637B |
$0.439B |
|
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
|
